Obinutuzumab, referred to as GA101, represents an novel antibody designed to treat chronic lymphocytic leukemia. The medication targets CD20 expressed on B lymphocytes, resulting in ADCC and destruction. Clinical https://www.targetmol.com/compound/obinutuzumab
Obinutuzumab (GA101): A Comprehensive Overview
Internet - 4 hours ago obinutuzumab099186Web Directory Categories
Web Directory Search
New Site Listings